Clinical Trials Directory

Trials / Completed

CompletedNCT05363904

Atopic Dermatitis: Sub-Saharan Africa vs. Central Europe

Environmental Impact and Immune Responses in Atopic Dermatitis Patients in Central Europe and Sub-Saharan Africa: A Prospective Study

Status
Completed
Phase
Study type
Observational
Enrollment
240 (actual)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Many people are affected by atopic dermatitis (AD) worldwide. However, clinical studies on AD in Sub-Saharan Africa are rare and there is a lack of knowledge about possible differences in pathogenesis between European and African AD. This study will collect clinical and laboratory data with the aim to compare clinical characteristics and immune responses in AD patients in Sub-Saharan Africa and Central Europe. Furthermore, relevant allergens as well as the nasal, skin and gut micro- and mycobiome will be investigated.

Detailed description

Objectives of the project: Compare the following aspects in patients suffering from atopic dermatitis (AD) and healthy control (HC) participants in Central Europe (CE) vs. Sub-Saharan Africa (SsA): * Clinical characteristics, life quality, treatments, and family history * Immune mapping and barrier characterization of lesional and non-lesional skin * Exploration of the serological and cutaneous immune signatures * Investigation of the skin, nasal and gut microbiome (including bacteria and fungi) * Comparison of the sensitization patterns and putting it into clinical context (food questionnaire, anamnesis about allergic symptoms, analysis of IgE and IgG levels)

Conditions

Interventions

TypeNameDescription
OTHERObservationQuestionnaires, Clinical Scores, Biomaterial Sampling

Timeline

Start date
2022-03-30
Primary completion
2025-03-12
Completion
2025-03-12
First posted
2022-05-06
Last updated
2025-07-09

Locations

3 sites across 3 countries: Madagascar, Switzerland, Tanzania

Source: ClinicalTrials.gov record NCT05363904. Inclusion in this directory is not an endorsement.